Huaiqihuang Granules in the Treatment of Primary Glomerulonephritis of Stage CKD3: a Randomized, Double-blind, Double-simulation, Positive Parallel Control Multi-center Clinical Study
Who is this study for? Adult patients with chronic kidney disease
What treatments are being studied? Huaiqihuang granules
Status: Recruiting
Location: See all (34) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Diagnosed as primary glomerulonephritis by renal biopsy
• Male or female, 18≤age≤65
• Blood pressure can be effectively controlled at or below 140/90mmHg
• 30mL/（min.1.73m2）≤ eGFR\<60mL/（min.1.73m2）
• 24-hour urine protein ration ≤ 2.0g/24h
• The participants must be capable of understanding and comply with the protocol and sign a written informed consent document
Locations
Other Locations
China
Anshan Central Hospital
RECRUITING
Anshan
Anshan Shuangshan Hospital
RECRUITING
Anshan
Ansteel Group General Hospital
RECRUITING
Anshan
The first affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology
RECRUITING
Baotou
Beijing Hospital
RECRUITING
Beijing
Benxi Iron and Steel General Hospital of Liaoning Health Industry Group
RECRUITING
Benxi
The First Bethune Hospital of Jilin University
RECRUITING
Changchun
The Second Hospital of Jilin University
RECRUITING
Changchun
Xiangya Hospital of Central South University
RECRUITING
Changsha
Changzhou NO.2 People's Hospital
RECRUITING
Changzhou
Affiliated Hospital of Chifeng University
RECRUITING
Chifeng
Dalian Ruikaier Nephropathy Hospital
RECRUITING
Dalian
The First Affiliated Hospital of Dalian Medical University
RECRUITING
Dalian
Zhejiang Provincial people's Hospital
RECRUITING
Hangzhou
The 2nd Affiliated Hospital of Harbin Medical University
RECRUITING
Harbin
Qilu Hospital of Shandong University
RECRUITING
Jinan
Kunming Yan'an Hospital
RECRUITING
Kunming
Lanzhou University Second Hospital
RECRUITING
Lanzhou
Jiangsu Province Hospital of Chinese Medicine
RECRUITING
Nanjing
The First Affiliated Hospital of Guangxi Medical University
RECRUITING
Nanning
The Sixth People's Hospital affiliated to Shanghai Jiaotong University
RECRUITING
Shanghai
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of medicine
RECRUITING
Shanghai
Central Hospital affiliated to Shenyang Medical College
RECRUITING
Shenyang
Shengjing Hospital of China Medical University (Nanhu Area)
RECRUITING
Shenyang
Shengjing Hospital of China Medical University( Huaxiang Area)
RECRUITING
Shenyang
The First Hospital of China Medical University
RECRUITING
Shenyang
The Fourth Hospital of Hebei Medical University
RECRUITING
Shijiazhuang
Second Hospital of Shanxi Medical University
RECRUITING
Taiyuan
Shanxi Provincial people's Hospital
RECRUITING
Taiyuan
The Second Hospital of Tianjin Medical University
RECRUITING
Tianjin
General Hospital of Ningxia Medical University
RECRUITING
Yinchuan
Yingkou Central Hospital
RECRUITING
Yingkou
The First Affiliated Hospital of Hebei North University
RECRUITING
Zhangjiakou
Henan Provincial people's Hospital
RECRUITING
Zhengzhou
Contact Information
Primary
Hongli Lin, MD
linhongli@vip.163.com
+86-13332268576
Backup
Dapeng Wang, MD
bobowdp@163.com
+86-18098875653
Time Frame
Start Date: 2020-06-30
Estimated Completion Date: 2026-03-30
Participants
Target number of participants: 466
Treatments
Experimental: Huaiqihuang group
Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
Active_comparator: Valsartan Group
Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
Authors
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital of Dalian Medical University
Collaborators: LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology